Salute e Benessere
LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market Penetration | DelveInsight
LUXTURNA (voretigene neparvovec-rzyl, AAV2-hRPE65v2) is a one-time gene therapy designed to treat vision loss caused by mutations in both copies of the RPE65 gene. It works by delivering a functional copy of the RPE65 gene to replace the faulty one, helping to restore vision. The therapy is administered as a single subretinal injection beneath the retina in patients with confirmed RPE65 mutations and viable retinal cells.
LUXTURNA was developed and commercialized in the US by Spark Therapeutics. Outside the US, Novartis holds the rights for development, registration, and commercialization under a licensing agreement. It is approved for treating vision loss caused by Leber's congenital amaurosis or retinitis pigmentosa due to confirmed biallelic RPE65 mutations.
LUXTURNA uses an adeno-associated viral type 2 (AAV2) vector to deliver the RPE65 gene. The vector includes a cytomegalovirus (CMV) enhancer and a chicken beta-actin promoter to drive the expression of the normal human RPE65 protein. The parent AAV2 virus, which serves as the template, is a non-pathogenic, single-stranded DNA virus that depends on a helper virus for replication. Once inside retinal cells, the functional RPE65 protein enables the regeneration of 11-cis-retinal, which improves light detection and restores vision.
In healthy individuals, RPE65 in retinal pigment epithelial cells converts all-trans-retinol into 11-cis-retinol, which then forms 11-cis-retinal—a critical step in the visual cycle that converts light into electrical signals. Mutations in the RPE65 gene disrupt this process, leading to vision loss. LUXTURNA restores the retinoid cycle by reintroducing functional RPE65 protein.
LUXTURNA is provided as a suspension for subretinal injection in a 0.5 mL extractable volume within a 2 mL single-dose vial. The concentration is 5 × 10¹² vg/mL, requiring a 1:10 dilution before use. The diluent is supplied in two single-use 2 mL vials.
Learn more about LUXTURNA projected market size for retinitis pigmentosa @
Retinitis pigmentosa is a group of inherited retinal disorders that cause progressive degeneration of the retina and eventual blindness. It involves the gradual bilateral deterioration of rod and cone photoreceptors, leading to night blindness and progressive loss of peripheral vision, followed by a decline in central vision due to the loss of cone function. Retinitis pigmentosa is primarily linked to genetic mutations, with over 44 associated genes identified. In 2023, approximately people in the US were affected by retinitis pigmentosa.
Currently, available treatments are mainly off-label and do not address the underlying genetic causes of retinitis pigmentosa. Patients without the RPE65 mutation rely on supportive care, such as vitamin supplements, protection from sunlight, and visual aids. LUXTURNA is the only approved therapy for retinitis pigmentosa but is limited to patients with the RPE65 mutation.
Gene and cell therapies are becoming key treatment strategies, targeting genes like RHO, USH2A, and RPGR. USH2A is a major focus, with two oligonucleotide candidates advancing in the RP pipeline. Optogenetics offers a novel gene therapy approach that works independently of specific gene mutations and shows promise in treating late-stage RP with severe photoreceptor loss.
Several companies have progressed optogenetic gene therapies into clinical trials. According to DelveInsight, the retinitis pigmentosa gene therapy market is expected to grow due to increasing disease prevalence, improved awareness and treatment access, and a strong pipeline of therapies across the 7MM.
Discover more about the retinitis pigmentosa market in detail @
Some of the drugs in the retinitis pigmentosa pipeline include (Johnson & Johnson Innovative Medicine/MeiraGT), (Beacon Therapeutics), (Nanoscope Therapeutics), (Gensight Biologics), (Coave Therapeutics), (Ocugen), (jCyte), (Endogena Therapeutics), (ProQR Therapeutics), (Aldeyra Therapeutics), and other.
In January 2025 , Beacon Therapeutics Holdings Limited reported that the FDA has awarded to laru-zova (laruparetigene zovaparvovec) for treating X-linked retinitis pigmentosa (XLRP).
To know more about the number of competing drugs in development, visit @
The company holds the following patents related to its AAV-based retinal gene therapy:
Spark Therapeutics holds exclusive licenses for three patent application families from CHOP, covering scalable methods for manufacturing high-purity gene therapy vectors. The first patent family pertains to the production of Spark's product candidates, including those under its collaboration with Pfizer. Patents from this family have been granted in
the United States ,
Australia , and Mexico , with expiration dates in 2021, not accounting for any potential extensions or adjustments. Related patent applications are still under review in
the United States ,
Brazil , Canada ,
China , Europe ,
Israel , India , and
Japan . If granted, these patents are expected to expire in 2031, excluding any possible extensions or adjustments.
Spark Therapeutics is advancing technology across multiple areas to enhance and broaden its current product pipeline. This technology, exclusively licensed from CHOP, focuses on modifying gene therapy vectors, incorporating companion therapies or diagnostics, and developing new therapeutic genes. The licensed patent portfolio includes:
Discover how LUXTURNA is shaping the retinitis pigmentosa treatment landscape @
The market for LUXTURNA is primarily driven by the and the as a viable treatment option. The has created a favorable environment for LUXTURNA. The therapy's ability to , reducing the burden of repeated treatments, has also contributed to its market acceptance. Furthermore, the , with its extensive commercialization and market access infrastructure, has helped expand . in the U.S. and Europe have further supported market uptake.
Despite its success, LUXTURNA faces significant market challenges. The , which exceeds for both eyes, poses a barrier to widespread adoption, even with reimbursement support. Access to treatment is also limited by the , which restricts the therapy's availability to select geographic regions. Moreover, as gene therapy technology evolves, the could pose competitive pressure. Additionally, the and , along with , adds to the operational challenges faced by Spark Therapeutics and Roche.
The future market dynamics of LUXTURNA are expected to be influenced by . in patient access programs and healthcare provider training could enhance market penetration. Additionally, the will play a crucial role in sustaining patient and physician confidence. As the gene therapy market matures, LUXTURNA's position as a space will likely provide it with a competitive edge, although it will need to navigate pricing pressures and emerging competition in the broader ophthalmology and gene therapy markets.
Dive deeper to get more insight into LUXTURNA's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key retinitis pigmentosa companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key retinitis pigmentosa companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cell and gene therapies in rare disorders companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gene therapy companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/luxturna-continues-to-lead-in-retinal-gene-therapy-with-increased-market-penetration--delveinsight-302407755.html